Nanomix Corporation Logo

Nanomix Corporation

NNMX

(2.0)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

4.900,00 USD

0% DER

0% Yield

0% NPM

Nanomix Corporation Stock Analysis

Nanomix Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nanomix Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (69.37%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-82%), which means it has a small amount of debt compared to the ownership it holds

4 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 ROA

The stock's ROA (-902.33%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Nanomix Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nanomix Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Nanomix Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nanomix Corporation Revenue
Year Revenue Growth
2010 428
2011 4.112 89.59%
2015 98.941 95.84%
2016 98.878 -0.06%
2017 29.356 -236.82%
2018 31.723 7.46%
2019 16.329 -94.27%
2020 60.375 72.95%
2021 141.778 57.42%
2022 15.450 -817.66%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nanomix Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2010 10.772
2011 194.276 94.46%
2015 352.788 44.93%
2016 83.844 -320.77%
2017 113.361 26.04%
2018 24.469 -363.28%
2019 1.562.912 98.43%
2020 4.184.820 62.65%
2021 3.017.263 -38.7%
2022 3.159.239 4.49%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nanomix Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 226.790
2011 408.454 44.48%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nanomix Corporation EBITDA
Year EBITDA Growth
2010 -241.208
2011 -811.510 70.28%
2015 -2.030.260 60.03%
2016 -1.193.570 -70.1%
2017 -1.198.660 0.42%
2018 -1.873.510 36.02%
2019 -3.343.590 43.97%
2020 -4.878.023 31.46%
2021 -5.660.552 13.82%
2022 -8.139.767 30.46%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nanomix Corporation Gross Profit
Year Gross Profit Growth
2010 30
2011 4.112 99.27%
2015 -141.529 102.91%
2016 4.731 3091.52%
2017 -84.690 105.59%
2018 -193.606 56.26%
2019 -158.710 -21.99%
2020 32.044 595.29%
2021 77.181 58.48%
2022 -69.458 211.12%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nanomix Corporation Net Profit
Year Net Profit Growth
2010 -248.295
2011 -827.168 69.98%
2015 -2.489.814 66.78%
2016 -3.737.524 33.38%
2017 -1.584.873 -135.82%
2018 -3.601.217 55.99%
2019 -3.694.079 2.51%
2020 -7.478.386 50.6%
2021 -11.682.209 35.98%
2022 -16.228.784 28.02%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nanomix Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 0
2011 0 0%
2015 -11 100%
2016 -15 21.43%
2017 -5 -180%
2018 -6 16.67%
2019 -6 -20%
2020 -1.740 99.71%
2021 -2 -86850%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nanomix Corporation Free Cashflow
Year Free Cashflow Growth
2010 -116.970
2011 0 0%
2015 -1.294.950 100%
2016 -1.249.624 -3.63%
2017 -1.279.906 2.37%
2018 -883.841 -44.81%
2019 -1.224.481 27.82%
2020 -3.959.490 69.07%
2021 -6.653.746 40.49%
2022 -6.112.582 -8.85%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nanomix Corporation Operating Cashflow
Year Operating Cashflow Growth
2010 -116.970
2011 0 0%
2015 -1.294.950 100%
2016 -1.249.624 -3.63%
2017 -1.275.202 2.01%
2018 -883.841 -44.28%
2019 -1.195.938 26.1%
2020 -3.916.069 69.46%
2021 -6.317.589 38.01%
2022 -6.085.990 -3.81%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nanomix Corporation Capital Expenditure
Year Capital Expenditure Growth
2010 0
2011 0 0%
2015 0 0%
2016 0 0%
2017 4.704 100%
2018 0 0%
2019 28.543 100%
2020 43.421 34.26%
2021 336.157 87.08%
2022 26.592 -1164.13%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nanomix Corporation Equity
Year Equity Growth
2010 533.889
2011 424.695 -25.71%
2012 696.463 39.02%
2013 3.345.270 79.18%
2014 74.663 -4380.49%
2015 -530.541 114.07%
2016 -3.118.860 82.99%
2017 -3.883.580 19.69%
2018 -4.145.917 6.33%
2019 -6.594.604 37.13%
2020 -12.525.505 47.35%
2021 -6.035.451 -107.53%
2022 -13.179.161 54.2%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nanomix Corporation Assets
Year Assets Growth
2010 980.138
2011 1.149.704 14.75%
2012 1.435.244 19.89%
2013 4.535.032 68.35%
2014 1.163.122 -289.9%
2015 878.034 -32.47%
2016 1.404.952 37.5%
2017 903.580 -55.49%
2018 1.439.299 37.22%
2019 23.781 -5952.31%
2020 530.471 95.52%
2021 905.712 41.43%
2022 982.055 7.77%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nanomix Corporation Liabilities
Year Liabilities Growth
2010 446.249
2011 725.009 38.45%
2012 738.781 1.86%
2013 1.189.762 37.91%
2014 1.088.459 -9.31%
2015 1.408.575 22.73%
2016 4.523.812 68.86%
2017 4.787.160 5.5%
2018 5.585.216 14.29%
2019 7.696.051 27.43%
2020 53.126.084 85.51%
2021 22.575.760 -135.32%
2022 14.814.747 -52.39%
2023 0 0%

Nanomix Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nanomix Corporation Dividends
Year Dividends Growth

Nanomix Corporation Profile

About Nanomix Corporation

Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.

CEO
Mr. David Gerald Ludvigson
Employee
30
Address
354 Merrimack Street
Lawrence, 01843

Nanomix Corporation Executives & BODs

Nanomix Corporation Executives & BODs
# Name Age
1 Mr. David Gerald Ludvigson
Interim Chief Executive Officer, President, Secretary & Director
70
2 Mr. Garrett P. Gruener
Founder & Executive Chairman
70
3 Mr. Vidur Sahney
Chief Operating Officer
70
4 Mr. Christopher R. Hetterly
Chief Financial Officer
70
5 Mr. Bradley Johnson Ph.D.
Chief Technology Officer
70

Nanomix Corporation Competitors